https://orcid.org/0000-0002-6093-7167
References
- Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry. 2006;163(11):1905–1917.
- Gaynes BN, Asher G, Gartlehner G, et al. Definition of treatment-resistant depression in the Medicare population. Rockville (MD): Agency for Healthcare Research and Quality; 2018.
- Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699.
- Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19(1):247.
- Zhdanava M, Kuvadia H, Joshi K, et al. Economic burden of treatment-resistant depression in privately insured U.S. patients with physical conditions. J Manag Care Spec Pharm. 2020;26(8):996–1007.
- Zhdanava M, Kuvadia H, Joshi K, et al. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder. Curr Med Res Opin. 2021;37(1):123–133.
- Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–438.
- Gelenberg AJ, Freeman MP, Markowitz JC, et al. The American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Washington, DC: American Psychiatric Publishing, Inc.; 2010. p. 1–152.
- Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893–903.
- Doherty T, Wajs E, Melkote R, et al. Cardiac safety of esketamine nasal spray in treatment-resistant depression: results from the clinical development program. CNS Drugs. 2020;34(3):299–310.
- U.S. Food and Drug Administration. SPRAVATO® (esketamine) prescribing information. Titusville (NJ): Janssen Pharmaceuticals, Inc.; 2020.
- U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. 2019. [cited 2021 June 7]. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified.
- U.S. Department of Health and Human Services. 45 CFR 46: pre-2018 requirements [cited 2020 Oct 16]. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html#46.101.
- Davis L, Uezato A, Newell JM, et al. Major depression and comorbid substance use disorders. Curr Opin Psychiatry. 2008;21(1):14–18.
- Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. York (UK): Centre for Reviews and Dissemination (UK); 2003. [cited 2022 June 6]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK70041/
- Cancino A, Leiva-Bianchi M, Serrano C, et al. Factors associated with psychiatric comorbidity in depression patients in primary health care in Chile. Depress Res Treat. 2018;2018:1–9.
- Ziobrowski HN, Leung LB, Bossarte RM, et al. Comorbid mental disorders, depression symptom severity, and role impairment among veterans initiating depression treatment through the Veterans Health Administration. J Affect Disord. 2021;290:227–236.